Floatz logo

Avdoralimab

SARS-CoV-2 (COVID-19) Infection

Centre Leon BerardPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the SARS-CoV-2 (COVID-19) Infection cohort.

View all 50

Same molecule, other indications

Avdoralimab is also rated in:

neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →